The Latest Cardiac and Vascular News
SAN FRANCISCO, Oct. 24, 2024 /PRNewswire/ — Avive Solutions, a leader in advanced cardiac response technology, is proud to announce a meaningful partnership with the Best Defense Foundation, a nonprofit organization dedicated to supporting military veterans. Through this collaboration,…
MCLEAN, Va., Oct. 24, 2024 /PRNewswire/ — Somatus, the nation’s largest and leading provider of value-based kidney and cardiovascular care, today announced it serves more than 275,000 patients in all 50 states and across all lines of business. The company’s growth is attributed to new…
Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs) Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs)
BERLIN and BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) — Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019.It leverages Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases.
Long-term strategic collaboration will support The AI Centre for Value-Based Healthcare’s mission and enable faster, more effective adoption of clinically proven AI tools across the NHS in London, the South of England and beyond deepc will deploy its AI operating system for radiology…
Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM University Hospital (Klinikum rechts der Isar der Technischen Universität or MRI), today announced a new framework agreement for the research and development of innovative radiopharmaceuticals and radionuclides for the treatment of cancer. This collaboration builds on a long-standing partnership and previously established cooperation agreement between ITM and TUM. The new agreement aims to further accelerate nuclear medicine initiatives by integrating ITM’s expertise in medical radioisotope production and radiopharmaceutical development with TUM’s cutting-edge research capabilities in nuclear physics (FRM II research reactor) and medical applications, alongside MRI’s renowned clinical expertise in diagnostics and patient care. The framework agreement also outlines how ITM and TUM will share and transfer the rights to any results or inventions that come from their future collaboration. Additional details of the framework agreement have not been disclosed.
LAS VEGAS–(BUSINESS WIRE)–Flosonics Medical, a leader in wearable medical ultrasound, was selected as a Best in Class of the Digital Health Awards, presented by the Digital Health Hub Foundation in a ceremony Monday afternoon in Las Vegas at HLTH, the global healthcare conference. “We are thrilled to be selected as a […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–TeraRecon, the leader in medical imaging advanced visualization, clinical AI, and workflow automation, today announced updates to its Intuition platform with new best-in-class cardiac magnetic resonance (MR) medical imaging capabilities. These clinical innovations are now available across all deployment models and on the latest cloud infrastructure. “We are […]
LOS GATOS, Calif., Oct. 23, 2024 /PRNewswire/ — Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced today the first-in-human trans-septal implantations using the 28 Fr. (French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved…
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
